We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tissue Sample Collection From Patients With Fanconi Anemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00899522
First Posted: May 12, 2009
Last Update Posted: May 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
May 9, 2009
May 12, 2009
May 19, 2014
August 2005
March 2013   (Final data collection date for primary outcome measure)
  • Creation of a Fanconi Anemia Cell Repository using rare solid tumor samples from patients with Fanconi anemia [ Time Frame: Duration of the study ]
  • Study tissue samples by molecular methods, including gene microarrays [ Time Frame: Duration of the study ]
  • Development of cancer cell lines from tissue archived from patients with Fanconi anemia [ Time Frame: Duration of the study ]
  • Creation of a Fanconi Anemia Cell Repository using rare solid tumor samples from patients with Fanconi anemia
  • Study tissue samples by molecular methods, including gene microarrays
  • Development of cancer cell lines from tissue archived from patients with Fanconi anemia
Complete list of historical versions of study NCT00899522 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tissue Sample Collection From Patients With Fanconi Anemia
Fanconi Anemia Cancer Cell Repository

RATIONALE: Collecting and storing samples of tumor tissue from patients with Fanconi anemia to test in the laboratory may help the study of cancer in the future.

PURPOSE: This laboratory study is collecting and storing tumor tissue samples from patients with Fanconi anemia.

OBJECTIVES:

  • Acquire rare solid tumor samples from patients with Fanconi anemia in order to create a Fanconi Anemia Cell Repository at the Oregon Health and Science University Cancer Institute.
  • Study repository tissue using a variety of molecular methods, including gene microarrays.
  • Develop cancer cell lines that are publicly available from tissue archived from patients with Fanconi anemia.

OUTLINE: Tumor biopsies are collected from patients with Fanconi anemia and archived for future molecular studies, cell line generation, and general usage by the research community at large. Medical information about the patient's cancer is also archived.

PROJECTED ACCRUAL: Not specified.

Observational
Observational Model: Case Control
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
To recruit participants into this project, an announcement will be posted on the Fanconi Anemia Research Fund website (http://www.fanconi.org/) after IRB approval is obtained.
  • Fanconi Anemia
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Unspecified Childhood Solid Tumor, Protocol Specific
  • Other: biologic sample preservation procedure
    Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
  • Procedure: biopsy
    Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
May 2013
March 2013   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Confirmed Fanconi anemia
  • Confirmed malignant solid tumor
  • Biopsy of tumor tissue available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Sexes Eligible for Study: All
1 Year to 55 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00899522
CDR0000445453
P30CA069533 ( U.S. NIH Grant/Contract )
OHSU-HEM-03022-LX
OHSU-IRB00001100
OSHU-CR00003822
Not Provided
Not Provided
Not Provided
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Grover C. Bagby, MD OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
May 2014